ProCE Banner Activity

Should We Switch to INSTIs in Treatment-Experienced PWH in Latin America?

Clinical Thought
Here’s my take on the latest data from the VISEND and 2SD studies presented at CROI 2022.

Released: March 04, 2022

Expiration: March 03, 2023

No longer available for credit.

Share

Faculty

Brenda E. Crabtree Ramírez

Brenda E. Crabtree Ramírez, MD

Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Cepheid

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Brenda E. Crabtree Ramírez, MD

Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico

Brenda E. Crabtree Ramírez, MD, has disclosed that she has received consulting fees from Janssen, MSD, and ViiV Healthcare.